May 7, 2020 / 1:01 PM / 23 days ago

BRIEF-Ovid Therapeutics Reports Q1 2020 Financial Results

May 7 (Reuters) - Ovid Therapeutics Inc:

* OVID THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q1 LOSS PER SHARE $0.37

* Q1 EARNINGS PER SHARE ESTIMATE $-0.33 — REFINITIV IBES DATA

* POSITIVE TOPLINE RESULTS FROM PHASE 2 ROCKET TRIAL OF OV101 FOR TREATMENT OF FRAGILE X SYNDROME

* EXPECT TO REPORT TOPLINE DATA FROM PIVOTAL PHASE 3 NEPTUNE TRIAL IN Q4 OF 2020

* AS OF MARCH 31, 2020, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $58.3 MILLION

* FULL RESULTS FROM PHASE 2 ARCADE TRIAL ARE EXPECTED IN EARLY 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below